ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW
Alvotech
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$5.03+0.03 (+0.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 50.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
59.8%
Operating margin
13.3%+219.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.7% | +91.9% | +54.5% | – | |
| Gross profit | +15.2% | +164.6% | – | – | |
| Operating income | +12.3% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 1.89 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | 9.71× | |
| Interest coverage | – | -0.9× | 0.5× | |
| Inventory turnover | – | – | 1.4× | |
| Capex to revenue | – | 11.2% | 11.0% | |
| Diluted shares | – | 94M | 291M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alvotech generated $1.14B from operations and spent $209.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.14B
Used
$209.71M
Capital expenditure$209.71M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$50.20M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$50.20M vs –
- Less leverageLong-term debt to assets fell84.8% → 84.9%
- Better liquidityCurrent ratio rose2.35 → 1.89
- No dilutionShare count did not rise268M → 291M
- Gross margin improvedGross margin up on the prior year62.16% → 59.82%
- More efficientAsset turnover rose0.52 → 0.48